MedPath

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Phase 2
Completed
Conditions
Head and Neck Cancer
Registration Number
NCT00002632
Lead Sponsor
Eastern Cooperative Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer.

Detailed Description

OBJECTIVES: I. Estimate the response rate in patients with metastatic or recurrent salivary gland cancer treated with paclitaxel (Taxol, TAX) by 3-hour infusion. II. Describe the toxicity of TAX in these patients.

OUTLINE: Single-Agent Chemotherapy. Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.

PROJECTED ACCRUAL: Up to 32 patients/histology will be entered. If no response is observed in the first 14 patients in a particular histology, accrual to that group will close; if after 18 months annual accrual is less than 10 patients/histology, accrual to that group may close.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (29)

Johns Hopkins Oncology Center

🇺🇸

Baltimore, Maryland, United States

Hahnemann University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

🇺🇸

Chicago, Illinois, United States

Veterans Affairs Medical Center - Chicago (Lakeside)

🇺🇸

Chicago, Illinois, United States

University of Pittsburgh Cancer Institute

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Minnesota Cancer Center

🇺🇸

Minneapolis, Minnesota, United States

CCOP - Missouri Valley Cancer Consortium

🇺🇸

Omaha, Nebraska, United States

Veterans Affairs Medical Center - Nashville

🇺🇸

Nashville, Tennessee, United States

Vanderbilt Cancer Center

🇺🇸

Nashville, Tennessee, United States

H. Lee Moffitt Cancer Center and Research Institute

🇺🇸

Tampa, Florida, United States

CCOP - Ann Arbor Regional

🇺🇸

Ann Arbor, Michigan, United States

Veterans Affairs Medical Center - Palo Alto

🇺🇸

Palo Alto, California, United States

Veterans Affairs Medical Center - Atlanta (Decatur)

🇺🇸

Decatur, Georgia, United States

Emory University Hospital - Atlanta

🇺🇸

Atlanta, Georgia, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

CCOP - Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

CCOP - Cedar Rapids Oncology Project

🇺🇸

Cedar Rapids, Iowa, United States

CCOP - Duluth

🇺🇸

Duluth, Minnesota, United States

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

CCOP - Northern New Jersey

🇺🇸

Hackensack, New Jersey, United States

Ireland Cancer Center

🇺🇸

Cleveland, Ohio, United States

Veterans Affairs Medical Center - East Orange

🇺🇸

East Orange, New Jersey, United States

Pretoria Academic Hospital

🇿🇦

Pretoria, South Africa

Albert Einstein Comprehensive Cancer Center

🇺🇸

Bronx, New York, United States

CCOP - Iowa Oncology Research Association

🇺🇸

Des Moines, Iowa, United States

Veterans Affairs Medical Center - Madison

🇺🇸

Madison, Wisconsin, United States

University of Wisconsin Comprehensive Cancer Center

🇺🇸

Madison, Wisconsin, United States

University of Rochester Cancer Center

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath